A $35 Billion Market
Looking for a Real Answer
By 2025, over one billion women globally have reached menopause. In the United States alone, approximately 1.3 million women enter menopause every year, and the perimenopause transition, which can begin a decade earlier, affects tens of millions more. The global menopause market was valued at $21.4 billion in 2025 and is projected to reach $35.6 billion by 2032, growing at 7.5% CAGR.
Despite this scale, the majority of women navigating this transition report that existing solutions are inadequate. The reasons why, and the gap this leaves, are set out in the next section.
Major media, celebrity advocacy, and a wave of femtech innovation are converging on this space at the same moment. The demand is enormous and underserved.
Perimenopause is the new frontier. Capital is following.
In September 2025, STAT News identified perimenopause as the fastest-growing category in women's health investment. Hims and Hers launched a dedicated perimenopause treatment line in October 2025. Flo Health launched its Perimenopause Score across both major app platforms. Private equity and venture capital are entering this space in force. Sovereign ECS enters at the right moment, with a formulation, delivery mechanism, and membership model that none of these new entrants can replicate.
What Women Are Being
Offered Is Not Enough
The conventional response to perimenopause and menopause has been fragmented, inadequate, and in many cases inaccessible. Hormone replacement therapy carries significant risk profiles and is contraindicated for large portions of the target population. Low-dose OTC supplements suffer from poor bioavailability and inconsistent efficacy. The wellness industry's offerings have been largely single-symptom, single-product, and disconnected from the whole-body biology of this transition.
What women actually need is a solution that addresses the underlying regulatory system, not just the surface symptoms. One that is natural, THC-free, non-hormonal, and genuinely bioavailable. One embedded in a broader support ecosystem that recognizes the emotional, spiritual, nutritional, and physiological complexity of this transition. Nothing in the current market offers all of this in a single coherent platform.
The gap is structural, not marginal. Existing CBD suppository products on the market use CBD-only or low-dose formulations that do not activate the full endocannabinoid system. Sovereign ECS deploys a broad-spectrum formulation at 120 to 150mg per unit, sitting at the center of a membership platform. That combination does not currently exist anywhere in the market.
The System Inside Every Woman
That Medicine Forgot
Inside every human body is a biological network that most women, and most doctors, have never been told about. It is called the endocannabinoid system, or ECS. It is one of the most widespread receptor networks in the human body, with receptors found throughout the brain, nervous system, immune tissue, reproductive organs, skin, and gut. Its primary function is homeostasis, the continuous work of keeping the body in balance.
During perimenopause and menopause, estrogen and progesterone levels fluctuate and decline, and these hormones interact directly with ECS receptor expression. As hormone levels shift, ECS function becomes dysregulated, contributing directly to the full spectrum of symptoms women experience. Supporting the ECS during this transition is not about replacing hormones. It is about helping the body's own systems regulate when and how those hormones are released, restoring its natural regulatory capacity.
Suppository delivery bypasses first-pass liver metabolism, delivering phytocannabinoids directly to the pelvic region where CB1 and CB2 receptors are densely expressed in the uterus, ovaries, and surrounding tissue. Bioavailability of 70 to 90% versus 6 to 20% for oral CBD products.
The 12-cannabinoid Sovereign ECS formulation, CBD, CBDA, CBG, CBGA, CBN, CBL, and additional minor cannabinoids, activates both CB1 and CB2 receptors simultaneously. Single-compound CBD isolate products activate neither receptor directly. The difference in therapeutic scope is categorical, not incremental.
THC-free, non-psychoactive, and entirely free of synthetic hormones. Broad-spectrum hemp-derived phytocannabinoids only. Safe for women who cannot or choose not to use HRT, and for those who want a natural whole-body approach that works with their biology.
A Formulation Built for
Precision and Purpose
Sovereign ECS delivers a complete clinical product range built around the broad-spectrum phytocannabinoid suppository at its center, complemented by topical and sublingual formats developed and owned outright by Sovereign ECS. Five years of research and development, including an active pilot study with real participants, underpin the formulation design.
All Sovereign ECS suppositories are formulated for rectal administration, taken every other day across the pack supply, for full-spectrum ECS activation.
| SKU | Route | Format | mg / Unit | Total Potency | MSRP | Target |
|---|---|---|---|---|---|---|
| Menstrual Support PMS | Rectal Only | 15 suppositories, 1-month | 150 mg | 2,250 mg | $109 | Women 18 to 45, cyclical symptoms |
| Menstrual Support, 3-month | Rectal Only | 45 suppositories, 3-month | 150 mg | 6,750 mg | $285 | Quarterly subscriber commit |
| Peri/Menopause | Rectal Only | 15 suppositories, 1-month | 120 mg | 1,800 mg | $99 | Women 40 to 60, hormonal transition |
| Peri/Menopause, 3-month | Rectal Only | 45 suppositories, 3-month | 120 mg | 5,400 mg | $255 | Quarterly subscriber commit |
| SKU | Format | MSRP | Target |
|---|---|---|---|
| Topical | 2oz unit | $53 | Localised pain, inflammation, skin support |
| Sublingual | 30ml, 1-month supply | $48 | Daily systemic ECS support |
The 3-month suppository packs reduce per-month cost for the customer and reduce shipping and fulfillment costs for the business, supporting the natural customer journey from monthly trial to quarterly commit once efficacy is established.
Regulatory and manufacturing position. Sovereign ECS suppositories are formulated from federally legal hemp-derived broad-spectrum phytocannabinoids containing no detectable THC, sitting within the 2018 Farm Bill framework that governs hemp-derived products in the United States. Production runs through in-house lab capacity at launch, transitioning to a vetted GMP-certified co-packer at the 2,000-pack monthly threshold. All raw cannabinoid inputs are sourced from suppliers providing batch-level Certificates of Analysis verified by ACS Laboratory. Payment processing, e-commerce, and shipping are handled through providers with established hemp-product compliance. The category remains state-by-state nuanced; Sovereign ECS ships to all states permitting hemp-derived broad-spectrum products and monitors regulatory developments through dedicated counsel.
More Than a Product.
A Complete Ecosystem.
Sovereign ECS operates on two tracks. The full product range is available to any customer at MSRP through the public storefront. The membership platform sits alongside this, giving members preferred product pricing and access to a structured women's wellness ecosystem delivered through a members-only digital platform. The product is the anchor. The membership is the moat. This model dramatically increases customer lifetime value, supports retention, and creates a category of loyalty that product-only businesses cannot replicate.
Members log in to the Sovereign ECS members-only website, where the experience is built as a guided program rather than a static library. The program is organized into six modules that cover the whole landscape of women's wellness, and content is released on a schedule so each month builds on the last, taking a member from her first pack through to a settled, supported routine. Members order suppositories, topicals, and sublingual at member pricing through the same platform, with delivery options spanning monthly subscription, quarterly commit, and one-off purchase.
Each module is a strand of the program, opened and refreshed across the member's journey rather than handed over all at once. Together they make up the full Sovereign ECS ecosystem.
What a member receives, month by month.
The program is sequenced so a member is never overwhelmed and always has a reason to return. Each phase opens new modules and builds on the one before it.
The membership fee is separate from the products.
Membership is a subscription to the platform and the program. It gives a member full access to the six modules, the community, the live calls, and member pricing on everything. She then buys the suppositories, topicals, and sublingual at the discounted member prices shown further below. The two are kept separate on purpose, so the value of the platform is clear in its own right.
The table below sets the non-member and member experiences side by side.
| Experience | Non-Member | Member |
|---|---|---|
| Purchase suppositories, topicals, sublingual | At MSRP | At member pricing (15 to 20% off) |
| Access 3-month suppository packs | At MSRP | At member pricing |
| Members-only website and content library | - | Full access |
| Six program modules of monthly guidance | - | Full access |
| Educational content, recipes, practices | - | Continuously updated library |
| Practitioner orientation consultation | - | Annual tier signup bonus |
| Welcome bundle on signup | - | Annual tier ($101 value) |
| Month-7 retention pack | - | Annual tier (up to $93 value) |
| Locked-in pricing | - | Annual tier, 12 months |
| Priority access to new product launches | - | All members |
All members access the Sovereign ECS product range at member pricing. The structure reflects member status as platform participants rather than retail customers.
| Product | MSRP | Member Price | Member Saves |
|---|---|---|---|
| Menstrual Suppository, 1-month | $109 | $93 | 15% |
| Menstrual Suppository, 3-month | $285 | $242 | 15% |
| Peri/Menopause Suppository, 1-month | $99 | $84 | 15% |
| Peri/Menopause Suppository, 3-month | $255 | $217 | 15% |
| Topical, 2oz | $53 | $42 | 20% |
| Sublingual, 30ml | $48 | $38 | 20% |
Annual member signup bonuses. Members joining at the annual tier receive a welcome bundle on signup (one topical and one sublingual at no charge, retail value $101), a complimentary 1-month suppository pack at month 7 as a retention reward (retail value up to $93), locked-in pricing for the full 12 months protecting against any future MSRP changes, a complimentary practitioner orientation consultation, and priority access to new product launches ahead of the wider member base. The combined Year 1 added value typically exceeds $200 in product and benefits, on top of the platform itself.
Subscription membership fundamentally changes the unit economics.
A one-time product purchase has a single revenue event. A membership subscriber generates recurring monthly revenue across an average relationship that, for women's wellness platforms, extends 18 to 36 months or more. Member pricing at 15 to 20 percent reflects platform participation rather than retail markup, and the per-unit margin on each product remains strong at every tier. The compounding economics come from the combination of recurring subscription revenue, repeat product purchases at protected margins, and the natural progression of members from monthly trial through quarterly commitment to annual partnership. A full-stack annual member purchasing the quarterly suppository pack alongside monthly topical and sublingual generates over $1,000 in annual gross contribution, before premium tier upgrades or affiliate income are counted.
Why Sovereign ECS
Cannot Be Easily Replicated
The women's hormonal wellness market is growing rapidly but remains dominated by single-symptom products, low-potency CBD offerings, and generic subscription boxes with no clinical anchor. Sovereign ECS occupies a position no current competitor holds, a precision-formulated, scientifically grounded ECS activation product embedded within a holistic membership platform.
| Brand / Product | mg / Unit | Cannabinoid Profile | MSRP | $/mg | Membership |
|---|---|---|---|---|---|
| Sovereign ECS Menstrual Us | 150 mg | 12 cannabinoids, broad-spectrum | $109 | $0.05 | Full platform |
| Sovereign ECS Peri/Menopause Us | 120 mg | 12 cannabinoids, broad-spectrum | $99 | $0.06 | Full platform |
| Foria Relief Melts | 100 mg | CBD only | $48 | $0.06 | None |
| Hello Again | ~25 mg | Full-spectrum with THC | $55 | $0.28 | None |
| Healing Rose | 100 mg | CBG and CBD only | $150 | $0.05 | None |
No competitor combines clinical-grade cannabinoid potency with a holistic membership platform. Sovereign ECS is 4 to 6 times better value per mg than Hello Again and significantly broader in cannabinoid profile than all current alternatives.
The calculation. Hello Again delivers approximately 25mg per unit at $55, or $0.28 per mg. Sovereign ECS Menstrual at 150mg per unit at $109 equals $0.05 per mg, 5.6 times better value. Sovereign ECS Peri/Menopause at 120mg per unit at $99 equals $0.06 per mg, 4.7 times better value.
What Sovereign ECS
Actually Delivers
The formulation is complete, owned outright, and already in the hands of real women. What sets it apart is not a single feature but the way the whole approach works with a woman's body. These are the benefits that drive trial, repeat purchase, and the word-of-mouth the business model depends on.
Early feedback from the women using it.
The group is small and the feedback is self-reported, but the women currently using Sovereign ECS have been consistently positive about how they feel. A few of their own words:
"Overall, much better than typical pre-menstrual symptoms."
"I feel like I handled my stressors better than I would have without it."
"My cycle seems to be regulating to a more normal length."
Benefits a woman can feel are what compound the economics.
A product that delivers a noticeable, whole-body difference is what turns a first purchase into a repeat purchase, a repeat purchase into a subscription, and a satisfied member into the organic word-of-mouth that the growth model is built on. The benefits above are not just clinical talking points. They are the engine behind the trial-to-repeat rate, the membership retention, and the lifetime value that underpin the financial projections that follow.
Three Raises. One Trajectory.
A Clear Path to Scale.
Sovereign ECS is structured around three raises that map to the stages of the business. The operational raise gets the business live, the product manufactured, and the first members subscribed using existing in-house lab capacity. The Founding Circle sits between the two, building the early growth runway for warm-network partners who want to come in after launch but ahead of full scaling. The growth raise is a social media and organic acquisition engine that drives customer numbers at scale. The projections below model the two raises that do the heavy lifting, operational and growth, with the Founding Circle bridging between them. Each is intentionally modest relative to the returns it is designed to unlock.
$10,000 to $30,000 to get Sovereign ECS live
This raise covers the essentials to move from pilot to commercial operation. At $10,000 the business launches in lean bootstrap mode using existing in-house lab capacity producing up to 60 packs per day. At $30,000 the launch is fuller, more initial inventory, a complete website and membership platform, and professional packaging ready for first subscribers. No co-packer is required at this stage. The business is cash-generative from the first sales at a 71 to 73% gross margin.
| Use of Operational Funds | $10k Scenario | $20k Scenario | $30k Scenario |
|---|---|---|---|
| Ingredients and initial batch production | $4,500 | $8,000 | $12,000 |
| Packaging, seals, boxes, labels | $2,000 | $3,500 | $5,000 |
| Website and membership platform | $1,500 | $4,000 | $6,500 |
| Legal, compliance, and IP basics | $1,000 | $2,500 | $4,000 |
| Working capital and contingency | $1,000 | $2,000 | $2,500 |
| Initial packs producible from raise | ~150 packs | ~280 packs | ~420 packs |
| Estimated Year 1 Revenue (organic only) | $45,000 to $70,000 | $85,000 to $130,000 | $130,000 to $200,000 |
| Estimated break-even timeline | ~10 months | ~8 months | ~6 months |
Revenue projections based on in-house production only, organic word-of-mouth and pilot network conversions, 40% trial-to-repeat rate, and average blended MSRP of $104 per pack. COGS of $29 per pack yields 72% gross margin. Reinvested gross profit funds ongoing batch production from month 2 onward.
$150,000 to $500,000 to fuel organic acquisition and scale
Once operational and generating initial revenue, the growth raise funds an education-led social media strategy across Instagram, TikTok, and Facebook, the primary acquisition channels for the Sovereign ECS target demographic. This is organic influencer and content-led marketing that builds brand authority and community, not paid advertising that disappears when the budget stops. At $150,000 this funds 12 to 18 months of consistent content, influencer partnerships, and community building. At $500,000 it funds a full two-to-three year acquisition engine that drives subscriber numbers to co-packer transition threshold, where COGS drop 20 to 30% and margins expand significantly.
| Growth Scenario | Social Raise | Year 1 Revenue | Year 2 Revenue | Year 3 Revenue | Gross Margin | Break-Even |
|---|---|---|---|---|---|---|
| Organic Bootstrap Only | $0 | $70K to $200K | $200K to $500K | $400K to $1.0M | 71 to 73% | 6 to 10 months |
| Partial Growth Raise | $150,000 | $300K to $550K | $700K to $1.3M | $1.6M to $2.6M | 73 to 76% | ~8 months |
| Full Growth Raise | $500,000 | $700K to $1.1M | $1.7M to $2.5M | $3.5M to $5.0M | 76 to 80% | ~6 months |
Growth scenarios modeled on 40 to 50% trial-to-repeat conversion, $80 to $120 blended CAC for social-funded scenarios, and co-packer transition at 2,000+ monthly packs enabling 20 to 30% COGS reduction from Year 2. Full growth scenario targets 3 to 5x investor return within 36 months. Comparable DTC CBD brand benchmarks: cbdMD 61 to 66% gross margin; Care/of 65 to 75%; Hims and Hers 70%+.
Where the growth capital goes.
The growth raise is structured to fund a content-led organic acquisition engine, not a paid-media campaign that disappears the moment the budget stops. Allocation is intentionally weighted toward durable assets, content, community, and member infrastructure, that continue working long after the deployment period.
| Allocation Category | % of Raise | $150K Scenario | $500K Scenario |
|---|---|---|---|
| Content production (video, photo, editorial) | 32% | $48,000 | $160,000 |
| Influencer and practitioner partnerships | 22% | $33,000 | $110,000 |
| Member platform, CRM, subscription infrastructure | 14% | $21,000 | $70,000 |
| Founder bandwidth and key hires | 12% | $18,000 | $60,000 |
| Paid social testing and amplification | 10% | $15,000 | $50,000 |
| Inventory scale and packaging upgrade | 6% | $9,000 | $30,000 |
| Legal, compliance, and IP protection | 4% | $6,000 | $20,000 |
Allocations are directional and may shift as channel performance data accumulates. The 10% paid social line is deliberately small at this stage, used for amplification of high-performing organic content and audience testing, not as the primary acquisition channel.
On the $80 to $120 CAC assumption. Comparable DTC women's wellness brands report blended CACs in the $60 to $150 range when organic content is the primary engine and paid social is used selectively. Hims and Hers reported $60 to $90 in their growth phase; Care/of reported $120 to $140 in the same window. The Sovereign ECS model is built on the lower-cost end of this range because the membership structure compounds lifetime value across multiple revenue streams. A single annual member purchasing the quarterly suppository pack generates approximately $300 in subscription revenue and $868 in product revenue over Year 1, yielding gross contribution of roughly $1,000 net of product COGS and signup incentives. Against a $100 CAC, that represents a 10x first-year contribution-to-acquisition ratio on the single-product member, rising further across the 18 to 36 month average member relationship and substantially higher for multi-product members. Actual CAC will be published quarterly to investors as the data accumulates.
From pilot conversions to a 1,000-member platform.
The subscription model drives the long-run economics. The table below reconciles the per-pack revenue projections with the member-base build expected to support them under the full growth raise scenario.
| Milestone | Active Members | Monthly Subscription ARR | Active Pack Volume / Month | Cumulative Revenue |
|---|---|---|---|---|
| Month 6 | 50 | $16,200 | ~120 packs | ~$80,000 to $110,000 |
| Month 12 | 250 | $81,000 | ~400 packs | ~$400,000 to $550,000 |
| Month 18, co-packer transition | 600 | $194,400 | ~900 packs | ~$900,000 to $1.3M |
| Month 24 | 1,000 | $324,000 | ~1,500 packs | ~$1.8M to $2.4M |
| Month 36 | 1,800 to 2,200 | $583K to $713K | ~2,800 packs | ~$3.5M to $5.0M |
Membership ARR calculated at a blended $27 per month, reflecting expected mix across monthly ($30), quarterly ($26.67 equivalent), and annual ($25 equivalent) tiers. Pack volume reflects combined member subscriptions and one-off non-member purchases at MSRP. Co-packer transition triggered at the 600-member mark when monthly pack volume reaches 2,000+ including member orders. Subscriber retention modeled at 18 to 36 month average, consistent with comparable women's wellness platforms. Cumulative revenue figures blend subscription ARR, member-priced product sales, and non-member MSRP sales. Schedule assumes full $500,000 growth raise; partial raise extends timeline by 6 to 12 months.
Multiple routes under active consideration.
The 3 to 5x target return within 36 months is supported by several realistic exit pathways currently under review with the senior team. Strategic acquisition, Series A at stepped-up valuation, and cash distribution from a mature margin-positive business are all viable structures for a business of this profile. Final exit framework and investor liquidity terms will be confirmed and shared with Founding Circle and Growth Raise participants ahead of close.
Science-Led.
Purpose-Driven.
"I spent 25 years in pharmaceutical and biotech development, working on autoimmune disease and cancer treatments at the highest levels of the industry. In 2017, I had a stroke. That event changed everything."
In the years that followed, Barry turned to the science his medical and pharmaceutical training had never introduced him to: the endocannabinoid system, the gut-brain axis, and the natural intelligence of the body when properly supported. The ECS had been quietly removed from medical curricula long before his generation entered the industry, leaving an entire field of physiology unfamiliar to both patients and practitioners. What he found there was extraordinary.
Sovereign ECS was born from that research and from conversations with women who had tried everything the conventional system offered and were still searching for something natural, sustainable, and aligned with how their bodies actually work. Barry brings a rare combination of genuine pharmaceutical science depth, five years of ECS-specific formulation research, and the conviction that comes from having experienced the limitations of conventional medicine firsthand.
Two operators joining at founding level.
The founder is being joined by two senior operators each taking equity at founding level. Profiles and full attribution available to qualified investors under NDA.
Three Entry Points.
One Compounding Opportunity.
Sovereign ECS offers three distinct participation opportunities, structured to meet investors where they are. The operational raise gets the business live. The Founding Circle builds the early growth runway and welcomes warm-network partners introduced through our senior team. The growth raise funds full-scale acquisition. Investors may participate in one, two, or all three stages. All are structured as equity and SAFE agreements designed to align long-term incentives and maximize upside at each stage.
A defined cohort, between operational launch and full growth.
The operational raise is intentionally modest, enough to get Sovereign ECS live and cash-generative. The growth raise is structured for institutional and lead-investor capital. Between these two sits a defined cohort of investors who recognize the opportunity early, bring meaningful capital at $30,000 to $150,000, and want a position that reflects entering before the full growth round. The Founding Circle is that cohort. It funds the early growth activity, content production, founder bandwidth, and initial influencer seeding, that bridges the business from operational launch to the full social acquisition engine. Members of the Founding Circle hold a preferred position relative to the growth raise and a defined relationship with the founder through the scaling phase.
The social media growth raise of $150,000 to $500,000 then funds the acquisition engine that takes a live, margin-positive product business to co-packer scale and beyond. The model is capital-efficient by design, high gross margins from launch mean every dollar works harder than in most comparable consumer wellness businesses.
An Honest View of
What Could Go Wrong
Every early-stage investment carries risk, and Sovereign ECS is no exception. We would rather set these out plainly than leave them for an investor to discover later. None of the points below changes our conviction in the opportunity, but each is real and worth weighing before any commitment.
How we manage these. The operational raise is deliberately small, so the business can become live and cash-generative before larger capital is deployed. Margins are strong from launch, the formulation is complete and owned outright, and the pilot is already generating real-world data. We share results, including actual customer acquisition cost, with investors as they accumulate. This is an early-stage opportunity, priced and structured to reflect that, and it should be considered only by investors comfortable with the risks above. Nothing here is legal or financial advice, and we encourage every prospective investor to take independent counsel before deciding.